av/cymabay-therapeutics--big.svg

NASDAQ:CBAY

CymaBay Therapeutics Inc

  • Stock

USD

Last Close

32.48

21/03 20:00

Market Cap

2.61B

Beta: 0.26

PE Ratio

−23.78

PFCF: −42.19

  • industry

    Biotechnology
  • exchange

    NASDAQ Global Select
  • website

    www.cymabay.com
  • ipo date

    Jan 16, 2014
  • full time employees

    60
  • currency

    USD

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in pha...Show More

Earnings

Earnings per Share (Estimate*)

-0.4-0.3-0.2-0.12015-05-072017-03-232019-02-282021-03-252023-03-16

Revenue (Estimate*)

5M10M15M20M25M30M35M2015-05-072017-03-232019-02-282021-03-252023-03-16

*Estimate based on analyst consensus

founders

  • Sujal Shah

num employees

  • 51-100

Please Sign In To Use The Chat

The chat is only available for registered users, please sign in or create your free account.